PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Perioperative Enfortumab Vedotin plus Pembrolizumab Cost-Effective in Cisplatin-Ineligible MIBC

enfortumab vedotinpembrolizumabnivolumabantibody-drug conjugatePD-1 inhibitormuscle-invasive bladder cancerurothelial carcinomacost-effectivenesscost-utility analysisMarkov modelKEYNOTE-905perioperative therapy Oncology Pharmacy

Background Information

Pembrolizumab plus enfortumab vedotin stands out as cost-effective for bladder cancer.

Patients with muscle-invasive bladder cancer (MIBC) who are ineligible or decline cisplatin have limited treatment options. Pembrolizumab with enfortumab vedotin (EV+Pem) offers a potential cost-effective alternative. EV+Pem improved quality-adjusted life-years (QALYs) by 2.56 and life-years by 3.08 compared to surgery with or without adjuvant nivolumab. The incremental cost-effectiveness ratio (ICER) was $52,117 per QALY. The treatment was cost-effective under a $100,000 per QALY threshold. Limitations include uncertainties in long-term survival projections and changing post-progression treatment patterns. EV+Pem provides a cost-effective treatment option for cisplatin-ineligible patients with MIBC.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Hill-McManus D, Lai Y, Bensimon AG, Young J, Reeve K, Tzontcheva A, Squires P, Li H, Ramamurthy C, Mossanen M

Citation: Hill-McManus D, Lai Y, Bensimon AG, et al. Cost-effectiveness of perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer in the United States. Journal of medical economics. 2026;29(1):2161-2176. doi:10.1080/13696998.2026.2713865

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.